Skip to main content
. 2024 Dec 10;12(12):e009683. doi: 10.1136/jitc-2024-009683

Figure 4. Allo-iMSC/CCL19 therapy modifies tumor microenvironment CT26-bearing mice were treated with PBS, syn-iMSC, allo-iMSC, syn-iMSC/CCL19 or allo-iMSC/CCL19 10 days after tumor inoculation. Tumors were harvested on 12 days and analyzed by RNA sequencing. (A) Principal component of each treatment group is shown. (B) Volcano plot showing log2 (fold change) and −log10(p value) for DEGs in No Tx (PBS) versus allo-iMSC/CCL19, allo-iMSC versus allo-iMSC/CCL19 and Syn-iMSC/CCL19 versus allo-iMSC/CCL19. (C) Gene Ontology analysis in No Tx (PBS) versus allo-iMSC/CCL19, allo-iMSC versus allo-iMSC/CCL19 and syn-iMSC/CCL19 versus allo-iMSC/CCL19 are shown. (D) Upregulated genes in syn-iMSC/CCL19 versus allo-iMSC/CCL19 group are shown in heatmap. RNA sequencing was performed once. CCL19, (C-C motif) ligand 19; iMSC, immortalized mesenchymal stem cell; NO Tx, no treatment, PBS, phosphate-buffered saline; syn-iMSC, syngeneic iMSC.

Figure 4